Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000905148-25-001760·Trevi Therapeutics, Inc.
Schedule 13G ownership disclosure
Trevi Therapeutics Inc
Common Stock, $0.001 par value per share · CUSIP: 89532M101
Event date: 2025-03-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- VIKING GLOBAL INVESTORS LP
Shares: 9,190,486 · Class: 8.7%
- Viking Global Opportunities Parent GP LLC
Shares: 9,190,486 · Class: 8.7%
- Viking Global Opportunities GP LLC
Shares: 6,157,625 · Class: 5.8%
- Viking Global Opportunities Portfolio GP LLC
Shares: 6,157,625 · Class: 5.8%
- Viking Global Opportunities Illiquid Investments Sub-Master LP
Shares: 6,157,625 · Class: 5.8%
- Viking Global Opportunities Drawdown GP LLC
Shares: 3,032,861 · Class: 2.9%
- Viking Global Opportunities Drawdown Portfolio GP LLC
Shares: 3,032,861 · Class: 2.9%
- Viking Global Opportunities Drawdown (Aggregator) LP
Shares: 3,032,861 · Class: 2.9%
- HALVORSEN OLE ANDREAS
Shares: 9,190,486 · Class: 8.7%
- Ott David C.
Shares: 9,190,486 · Class: 8.7%
- Shabet Rose Sharon
Shares: 9,190,486 · Class: 8.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000905148-25-001760
- Form type
- SCHEDULE 13G/A
- Filer
- Trevi Therapeutics, Inc.
- CIK
- CIK 1563880
- Filed
- May 15, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership